Wells P - Search Results

1

A general method to correct PET data for tissue metabolites using a dual-scan approach.

Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, Cunningham VJ. Gunn RN, et al. Among authors: wells p. J Nucl Med. 2000 Apr;41(4):706-11. J Nucl Med. 2000. PMID: 10768573 Free article.

2

Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies.

Wells P, Gunn RN, Alison M, Steel C, Golding M, Ranicar AS, Brady F, Osman S, Jones T, Price P. Wells P, et al. Cancer Res. 2002 Oct 15;62(20):5698-702. Cancer Res. 2002. PMID: 12384527 Clinical Trial.

3

2-[11C]thymidine positron emission tomography reproducibility in humans.

Wells P, Gunn RN, Steel C, Ranicar AS, Brady F, Osman S, Jones T, Price P. Wells P, et al. Clin Cancer Res. 2005 Jun 15;11(12):4341-7. doi: 10.1158/1078-0432.CCR-04-1818. Clin Cancer Res. 2005. PMID: 15958616 Free article.

4

On-line measurement of exhaled [11C]CO2 during PET.

Gunn RN, Ranicar A, Yap JT, Wells P, Osman S, Jones T, Cunningham VJ. Gunn RN, et al. Among authors: wells p. J Nucl Med. 2000 Apr;41(4):605-11. J Nucl Med. 2000. PMID: 10768560 Free article.

5

2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.

Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR. Wells P, et al. J Natl Cancer Inst. 2003 May 7;95(9):675-82. doi: 10.1093/jnci/95.9.675. J Natl Cancer Inst. 2003. PMID: 12734319

6

Assessment of inter- and intrapatient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers.

Wells P, Jones T, Price P. Wells P, et al. Clin Cancer Res. 2003 Dec 15;9(17):6350-6. Clin Cancer Res. 2003. PMID: 14695134

7

Positron emission tomography: a new investigational area for cancer research.

Wells P, Harte RJ, Price P. Wells P, et al. Clin Oncol (R Coll Radiol). 1996;8(1):7-14. doi: 10.1016/s0936-6555(05)80033-0. Clin Oncol (R Coll Radiol). 1996. PMID: 8688368 Review. No abstract available.

8

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.

Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL. Anderson H, et al. Among authors: wells p. Br J Cancer. 2003 Jul 21;89(2):262-7. doi: 10.1038/sj.bjc.6601105. Br J Cancer. 2003. PMID: 12865914 Free PMC article. Clinical Trial.

9

Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.

Wells P, West C, Jones T, Harris A, Price P. Wells P, et al. Biochim Biophys Acta. 2004 Dec 17;1705(2):91-102. doi: 10.1016/j.bbcan.2004.09.007. Biochim Biophys Acta. 2004. PMID: 15588764 Review.

10

Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.

Meikle SR, Matthews JC, Brock CS, Wells P, Harte RJ, Cunningham VJ, Jones T, Price P. Meikle SR, et al. Among authors: wells p. Cancer Chemother Pharmacol. 1998;42(3):183-93. doi: 10.1007/s002800050804. Cancer Chemother Pharmacol. 1998. PMID: 9685053

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,508 results

Search Page

Filters